News

Verastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer Treatment
Verastem Oncology said Wednesday that the Food and Drug Administration cleared the company's investigational new drug application for its potential treatment of certain cancers.
Verastem Oncology to initiate trial for its targeted cancer therapy
Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application ...
Patient with rare cancer first in US to be treated with highly accurate proton beam arc therapy
For many cancer patients, side effects from radiation can be debilitating. But a new way of delivering radiation treatment ...
Targeted Oncology18h
Managing Colorectal Cancer Requires Using All Available Options
In an interview with Peers & Perspectives in Oncology, John L. Marshall, MD, discussed treatment approaches and sequencing ...
Targeted Oncology2d
The Targeted Pulse: FDA Approvals in HCC and CRC, Promise for SCLC, and More
The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.
Fierce Pharma2d
Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...
Santé log5d
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Paris and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic ...
Verywell Health5d
Understanding Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...